These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 16164038)

  • 1. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
    Marsac D; Puaux AL; Rivière Y; Michel ML
    Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen.
    Le Borgne S; Mancini M; Le Grand R; Schleef M; Dormont D; Tiollais P; Rivière Y; Michel ML
    Virology; 1998 Jan; 240(2):304-15. PubMed ID: 9454704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses.
    Negri DR; Buffa V; Leone P; Bona R; Borghi M; Carlini F; De Angelis F; Indraccolo S; Ensoli B; Cara A
    J Immunol Methods; 2004 Aug; 291(1-2):153-63. PubMed ID: 15345313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles.
    Puaux AL; Marsac D; Prost S; Singh MK; Earl P; Moss B; Le Grand R; Riviere Y; Michel ML
    Vaccine; 2004 Sep; 22(27-28):3535-45. PubMed ID: 15315833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization.
    Loirat D; Lemonnier FA; Michel ML
    J Immunol; 2000 Oct; 165(8):4748-55. PubMed ID: 11035120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
    Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
    J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
    Wild J; Bojak A; Deml L; Wagner R
    Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
    Zhou C; Peng G; Jin X; Tang J; Chen Z
    Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
    Ishioka GY; Fikes J; Hermanson G; Livingston B; Crimi C; Qin M; del Guercio MF; Oseroff C; Dahlberg C; Alexander J; Chesnut RW; Sette A
    J Immunol; 1999 Apr; 162(7):3915-25. PubMed ID: 10201910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.
    Bolesta E; Gzyl J; Wierzbicki A; Kmieciak D; Kowalczyk A; Kaneko Y; Srinivasan A; Kozbor D
    Virology; 2005 Feb; 332(2):467-79. PubMed ID: 15680412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.
    Nayersina R; Fowler P; Guilhot S; Missale G; Cerny A; Schlicht HJ; Vitiello A; Chesnut R; Person JL; Redeker AG; Chisari FV
    J Immunol; 1993 May; 150(10):4659-71. PubMed ID: 7683326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.